Option Care Health selected to provide VILTEPSO
By HME News Staff
Updated Fri September 4, 2020
BANNOCKBURN, Ill. - Option Care Health has been chosen to participate in a limited distribution network for VILTEPSO (viltolarsen) for patients with Duchenne Muscular Dystrophy who are amenable to exon 53 skipping therapy. Viltepso is among a growing number of chronic infusion therapies for neuromuscular disorders that Option Care Health is able to deliver to patients at home or in one of the company's more than 125 ambulatory infusion suites across the country. “Our demonstrated track record of collaboration with manufacturers to extend infusion services for new therapies to alternate treatment sites, coupled with our personalized clinical care, leads to better outcomes and higher patient satisfaction,” said Matt Dans, senior vice president of development for Option Care Health.
Comments